Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup phase III BIG 02-98 trial

Bernhard C. Pestalozzi, P. Francis, E. Quinaux, S. Dolci, E. Azambuja, R. D. Gelber, G. Viale, A. Balil, M. Andersson, B. Nordenskjöd, M. Gnant, J. Gutierrez, I. Láng, J. P A Crown, M. Piccart-Gebhart

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Breast cancer central nervous system (CNS) metastases are an increasingly important problem because of high CNS relapse rates in patients treated with trastuzumab and/or taxanes. Patients and methods: We evaluated data from 2887 node-positive breast cancer patients randomised in the BIG 02-98 trial comparing anthracycline-based adjuvant chemotherapy (control arms) to anthracycline-docetaxel-based sequential or concurrent chemotherapy (experimental arms). After a median follow-up of 5 years, 403 patients had died and detailed information on CNS relapse was collected for these patients. Results: CNS relapse occurred in 4.0% of control patients and3.7% of docetaxel-treated patients. CNS relapse occurred in 27% of deceased patients in both treatment groups. CNS relapse was usually accompanied by neurologic symptoms (90%), and 25% of patients with CNS relapse died without evidence of extra-CNS relapse. Only 20% of patients survived 1 year from the diagnosis of CNS relapse. Prognosis of CNS relapse was worse for patients with meningeal carcinomatosis when compared with brain metastases. Unexpected findings included a higher rate of positive cerebrospinal fluid cytology (8% versus 3%) and more frequent use of magnetic resonance imaging for diagnosis (47% versus 30%) in the docetaxel-treated patients. Conclusion: There is no evidence that adjuvant docetaxel treatment is associated with an increased frequency of CNS relapse.

Original languageEnglish
Pages (from-to)1837-1841
Number of pages5
JournalAnnals of Oncology
Volume19
Issue number11
DOIs
Publication statusPublished - 2008

Fingerprint

Central Nervous System
docetaxel
Breast Neoplasms
Recurrence
Therapeutics
Anthracyclines
taxane
Meningeal Carcinomatosis
Neoplasm Metastasis
Taxoids
Adjuvant Chemotherapy
Neurologic Manifestations
Cell Biology
Cerebrospinal Fluid
Magnetic Resonance Imaging
Drug Therapy
Brain

Keywords

  • Adjuvant chemotherapy
  • Breast cancer
  • Central nervous system
  • Meningeal carcinomatosis
  • Taxane
  • Trastuzumab

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup phase III BIG 02-98 trial. / Pestalozzi, Bernhard C.; Francis, P.; Quinaux, E.; Dolci, S.; Azambuja, E.; Gelber, R. D.; Viale, G.; Balil, A.; Andersson, M.; Nordenskjöd, B.; Gnant, M.; Gutierrez, J.; Láng, I.; Crown, J. P A; Piccart-Gebhart, M.

In: Annals of Oncology, Vol. 19, No. 11, 2008, p. 1837-1841.

Research output: Contribution to journalArticle

Pestalozzi, BC, Francis, P, Quinaux, E, Dolci, S, Azambuja, E, Gelber, RD, Viale, G, Balil, A, Andersson, M, Nordenskjöd, B, Gnant, M, Gutierrez, J, Láng, I, Crown, JPA & Piccart-Gebhart, M 2008, 'Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup phase III BIG 02-98 trial', Annals of Oncology, vol. 19, no. 11, pp. 1837-1841. https://doi.org/10.1093/annonc/mdn385
Pestalozzi, Bernhard C. ; Francis, P. ; Quinaux, E. ; Dolci, S. ; Azambuja, E. ; Gelber, R. D. ; Viale, G. ; Balil, A. ; Andersson, M. ; Nordenskjöd, B. ; Gnant, M. ; Gutierrez, J. ; Láng, I. ; Crown, J. P A ; Piccart-Gebhart, M. / Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup phase III BIG 02-98 trial. In: Annals of Oncology. 2008 ; Vol. 19, No. 11. pp. 1837-1841.
@article{c3fc25c7fdb6498cb6a984a605852afc,
title = "Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup phase III BIG 02-98 trial",
abstract = "Background: Breast cancer central nervous system (CNS) metastases are an increasingly important problem because of high CNS relapse rates in patients treated with trastuzumab and/or taxanes. Patients and methods: We evaluated data from 2887 node-positive breast cancer patients randomised in the BIG 02-98 trial comparing anthracycline-based adjuvant chemotherapy (control arms) to anthracycline-docetaxel-based sequential or concurrent chemotherapy (experimental arms). After a median follow-up of 5 years, 403 patients had died and detailed information on CNS relapse was collected for these patients. Results: CNS relapse occurred in 4.0{\%} of control patients and3.7{\%} of docetaxel-treated patients. CNS relapse occurred in 27{\%} of deceased patients in both treatment groups. CNS relapse was usually accompanied by neurologic symptoms (90{\%}), and 25{\%} of patients with CNS relapse died without evidence of extra-CNS relapse. Only 20{\%} of patients survived 1 year from the diagnosis of CNS relapse. Prognosis of CNS relapse was worse for patients with meningeal carcinomatosis when compared with brain metastases. Unexpected findings included a higher rate of positive cerebrospinal fluid cytology (8{\%} versus 3{\%}) and more frequent use of magnetic resonance imaging for diagnosis (47{\%} versus 30{\%}) in the docetaxel-treated patients. Conclusion: There is no evidence that adjuvant docetaxel treatment is associated with an increased frequency of CNS relapse.",
keywords = "Adjuvant chemotherapy, Breast cancer, Central nervous system, Meningeal carcinomatosis, Taxane, Trastuzumab",
author = "Pestalozzi, {Bernhard C.} and P. Francis and E. Quinaux and S. Dolci and E. Azambuja and Gelber, {R. D.} and G. Viale and A. Balil and M. Andersson and B. Nordenskj{\"o}d and M. Gnant and J. Gutierrez and I. L{\'a}ng and Crown, {J. P A} and M. Piccart-Gebhart",
year = "2008",
doi = "10.1093/annonc/mdn385",
language = "English",
volume = "19",
pages = "1837--1841",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup phase III BIG 02-98 trial

AU - Pestalozzi, Bernhard C.

AU - Francis, P.

AU - Quinaux, E.

AU - Dolci, S.

AU - Azambuja, E.

AU - Gelber, R. D.

AU - Viale, G.

AU - Balil, A.

AU - Andersson, M.

AU - Nordenskjöd, B.

AU - Gnant, M.

AU - Gutierrez, J.

AU - Láng, I.

AU - Crown, J. P A

AU - Piccart-Gebhart, M.

PY - 2008

Y1 - 2008

N2 - Background: Breast cancer central nervous system (CNS) metastases are an increasingly important problem because of high CNS relapse rates in patients treated with trastuzumab and/or taxanes. Patients and methods: We evaluated data from 2887 node-positive breast cancer patients randomised in the BIG 02-98 trial comparing anthracycline-based adjuvant chemotherapy (control arms) to anthracycline-docetaxel-based sequential or concurrent chemotherapy (experimental arms). After a median follow-up of 5 years, 403 patients had died and detailed information on CNS relapse was collected for these patients. Results: CNS relapse occurred in 4.0% of control patients and3.7% of docetaxel-treated patients. CNS relapse occurred in 27% of deceased patients in both treatment groups. CNS relapse was usually accompanied by neurologic symptoms (90%), and 25% of patients with CNS relapse died without evidence of extra-CNS relapse. Only 20% of patients survived 1 year from the diagnosis of CNS relapse. Prognosis of CNS relapse was worse for patients with meningeal carcinomatosis when compared with brain metastases. Unexpected findings included a higher rate of positive cerebrospinal fluid cytology (8% versus 3%) and more frequent use of magnetic resonance imaging for diagnosis (47% versus 30%) in the docetaxel-treated patients. Conclusion: There is no evidence that adjuvant docetaxel treatment is associated with an increased frequency of CNS relapse.

AB - Background: Breast cancer central nervous system (CNS) metastases are an increasingly important problem because of high CNS relapse rates in patients treated with trastuzumab and/or taxanes. Patients and methods: We evaluated data from 2887 node-positive breast cancer patients randomised in the BIG 02-98 trial comparing anthracycline-based adjuvant chemotherapy (control arms) to anthracycline-docetaxel-based sequential or concurrent chemotherapy (experimental arms). After a median follow-up of 5 years, 403 patients had died and detailed information on CNS relapse was collected for these patients. Results: CNS relapse occurred in 4.0% of control patients and3.7% of docetaxel-treated patients. CNS relapse occurred in 27% of deceased patients in both treatment groups. CNS relapse was usually accompanied by neurologic symptoms (90%), and 25% of patients with CNS relapse died without evidence of extra-CNS relapse. Only 20% of patients survived 1 year from the diagnosis of CNS relapse. Prognosis of CNS relapse was worse for patients with meningeal carcinomatosis when compared with brain metastases. Unexpected findings included a higher rate of positive cerebrospinal fluid cytology (8% versus 3%) and more frequent use of magnetic resonance imaging for diagnosis (47% versus 30%) in the docetaxel-treated patients. Conclusion: There is no evidence that adjuvant docetaxel treatment is associated with an increased frequency of CNS relapse.

KW - Adjuvant chemotherapy

KW - Breast cancer

KW - Central nervous system

KW - Meningeal carcinomatosis

KW - Taxane

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=54949136570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54949136570&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdn385

DO - 10.1093/annonc/mdn385

M3 - Article

C2 - 18562328

AN - SCOPUS:54949136570

VL - 19

SP - 1837

EP - 1841

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 11

ER -